Autonomix Medical, Inc. Announces Appointment of Christopher C. Capelli, M.D. to Board of Directors

THE WOODLANDS, TX, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Christopher C. Capelli, M.D. to its Board of Directors.

“We are pleased to welcome Dr. Capelli to our board of directors. He brings with him a wealth of knowledge and expertise, amassed over a noteworthy career. We believe Dr. Capelli will undoubtably be a valuable part of the team as we continue to advance the Company and our novel approach to how diseases involving the peripheral nervous system are diagnosed and treated,” commented Lori Bisson, Chief Executive Officer of Autonomix.

“This is an exciting time for Autonomix. The team is building momentum and strengthening its position among multiple audiences. I believe the Autonomix technology has promising potential to address a wide array of indications and play a significant role in revolutionizing pain management. I look forward to working closely with the team and progressing toward clinical studies and unlocking the full potential of this much-needed technology,” added Dr. Capelli.

Dr. Capelli currently serves as the Scientific Officer & Medical Device Advisor-Soliton for Allergan Aesthetics R&D Surgical Devices at AbbVie. Prior to being acquired by AbbVie in December 2021, he was the Vice Chairman of the Board, Chief Science Officer and Co-founder for Soliton, Inc., a medical device company that was commercializing RESONIC for the dermatologic esthetics marketplace based on its Rapid Acoustic Pulse (RAP) technology. Dr. Capelli was the lead inventor of the RAP technology.

From March 2005 through August 2014, Dr. Capelli served as the vice president in the office of Technology Based Ventures at The University of Texas M.D. Anderson Cancer Center (UTMDACC). From March 2001 through February 2005, Dr. Capelli served the director of the Office of Technology Management at the University of Pittsburgh (UPitt). In both these positions, Dr. Capelli played a leading role in enabling the commercialization of products and services originating from both UTMDACC and UPitt. This included acting as the principal executive in the initiation, formation, and negotiation of institutional collaborations with industry partners for the development of healthcare business ventures based on new technologies. From 1987 through 1998, Dr. Capelli served the president and was the founder of BioInterface Technologies, Inc. This company developed new silver-based antimicrobial technologies for use in wound care medical products sold by Coloplast A/S in Europe.

A graduate of Massachusetts Institute of Technology (MIT) with a Bachelor of Science degree in Mechanical Engineering, Dr. Capelli earned his MD from the University of Wisconsin Medical School and maintains a medical license in the State of Wisconsin. As a result of his scientific work since graduating from MIT, Dr. Capelli holds over 100 issued patents and patent applications worldwide. These patents served as the basis for the creation of 5 companies. As a businessman, Dr. Capelli has been directly involved in the start-up of numerous venture-capital backed biomedical company ventures.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing our technology for pancreatic cancer pain and pancreatitis pain, conditions that can cause debilitating pain and need an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.

For more information, visit and connect with the Company on Twitter, LinkedIn and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Autonomix to successfully develop its technology platform on a timely basis. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’

Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.

Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page ( Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.

Investor Relations Contact
Jenene Thomas